Septerna (NASDAQ:SEPN) Stock Rating Upgraded by Zacks Research

Septerna (NASDAQ:SEPN) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Raymond James Financial started coverage on shares of Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price target for the company. HC Wainwright increased their price target on shares of Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, JonesTrading began coverage on shares of Septerna in a report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Septerna currently has an average rating of “Moderate Buy” and a consensus price target of $33.83.

Septerna Stock Down 2.8%

Septerna stock opened at $29.99 on Tuesday. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -19.86 and a beta of 3.85. The business has a 50-day simple moving average of $26.90 and a 200 day simple moving average of $22.09. Septerna has a 52 week low of $4.66 and a 52 week high of $32.63.

Insider Activity at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Septerna

Several institutional investors have recently added to or reduced their stakes in SEPN. Group One Trading LLC increased its holdings in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC bought a new position in Septerna during the 4th quarter worth approximately $35,000. Russell Investments Group Ltd. bought a new position in Septerna during the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new position in Septerna in the 4th quarter worth approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Septerna in the fourth quarter valued at approximately $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.